Home » KERYX TO PRESENT PHASE II RESULTS AT CONFERENCE
KERYX TO PRESENT PHASE II RESULTS AT CONFERENCE
Keryx Biopharmaceuticals has announced that final data from the company's Phase II study of KRX-101 (oral sulodexide gelcap) for diabetic nephropathy will be presented at the upcoming American Society of Nephrology's Renal Week in Philadelphia, Pa.
KRX-101, the company's lead compound for the treatment of diabetic nephropathy, is currently in a global pivotal Phase III and Phase IV clinical program.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May